Genetic Signatures Limited (ASX:GSS)
Australia · Delayed Price · Currency is AUD | Market Cap | 13.17M -81.3% |
| Revenue (ttm) | 19.94M +6.8% |
| Net Income | -11.27M |
| EPS | -0.05 |
| Shares Out | 227.14M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 336,404 |
| Open | 0.0600 |
| Previous Close | 0.0610 |
| Day's Range | 0.0580 - 0.0610 |
| 52-Week Range | 0.0510 - 0.4300 |
| Beta | 0.51 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 28, 2026 |
About Genetic Signatures
Genetic Signatures Limited operates as a molecular diagnostic company in Australia, the Asia Pacific, Europe, the Middle East, Asia, and the Americas. It offers enteric bacteria, Enteroaggregative E.coli aggR and aaiC, enteric viral, enteric protozoan, enteric protozoan extended, enteric microsporidia, respiratory pathogen, SARS-CoV-2, extended respiratory, atypical respiratory, Measles, Mumps, and Rubella detection kits under the EasyScreen name. The company was incorporated in 2001 and is headquartered in Newtown, Australia. [Read more]
Financial Performance
In fiscal year 2025, Genetic Signatures's revenue was 19.75 million, an increase of 43.47% compared to the previous year's 13.77 million. Losses were -20.10 million, 12.6% more than in 2024.
Financial StatementsNews
Genetic Signatures Transcript: Investor update
A comprehensive restructuring delivered AUD 5 million in annualized cost savings and reset leadership, while product upgrades and new supply agreements strengthened positions in EMEA and Australia. U.S. market entry and major instrument projects are paused pending strategic review.
Genetic Signatures Slides: Investor update
Genetic Signatures has posted slides in relation to its latest quarterly earnings report, which was published on June 9, 2026.
Genetic Signatures Earnings release: Q3 2026
Genetic Signatures released its Q3 2026 earnings on April 28, 2026, summarizing the period's financial results.
Genetic Signatures Earnings Call Transcript: H1 2026
Revenue rose slightly to AUD 8.7 million, but gross margin declined due to higher costs. U.S. expansion remains a focus, with new customers and product development underway, while a forensic review targets cost reductions to address high cash burn.
Genetic Signatures Quarterly report: H1 2026
Genetic Signatures has published its H1 2026 quarterly earnings report on February 25, 2026.
Genetic Signatures Slides: H1 2026
Genetic Signatures has posted slides in relation to its H1 2026 quarterly earnings report, which was published on February 25, 2026.
Genetic Signatures Earnings release: H1 2026
Genetic Signatures released its H1 2026 earnings on February 25, 2026, summarizing the period's financial results.
Genetic Signatures Slides: FY 2025
Genetic Signatures has posted slides in relation to its FY 2025 quarterly earnings report, which was published on November 16, 2025.
Genetic Signatures Earnings release: Q1 2026
Genetic Signatures released its Q1 2026 earnings on October 20, 2025, summarizing the period's financial results.
Genetic Signatures Earnings Call Transcript: H2 2025
Revenue grew 63% to $15.9M with gross margin at 55%, driven by strong respiratory and EMEA sales. Strategic refocus, new automation partnerships, and disciplined cost management position the company for future growth despite a $20.1M loss and slower U.S. uptake.
Genetic Signatures Annual report: H2 2025
Genetic Signatures has published its H2 2025 annual report on August 24, 2025.
Genetic Signatures Slides: H2 2025
Genetic Signatures has posted slides in relation to its H2 2025 quarterly earnings report, which was published on August 24, 2025.
Genetic Signatures Earnings release: H2 2025
Genetic Signatures released its H2 2025 earnings on August 24, 2025, summarizing the period's financial results.